Compare SUVEN LIFE with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES DIVIS LABORATORIES SUVEN LIFESCIENCES/
DIVIS LABORATORIES
 
P/E (TTM) x 19.7 31.5 62.4% View Chart
P/BV x 4.0 7.1 56.1% View Chart
Dividend Yield % 0.5 0.6 83.7%  

Financials

 SUVEN LIFESCIENCES   DIVIS LABORATORIES
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
DIVIS LABORATORIES
Mar-18
SUVEN LIFESCIENCES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3381,142 29.6%   
Low Rs169533 31.8%   
Sales per share (Unadj.) Rs52.1146.6 35.6%  
Earnings per share (Unadj.) Rs6.833.0 20.7%  
Cash flow per share (Unadj.) Rs8.638.4 22.3%  
Dividends per share (Unadj.) Rs1.5010.00 15.0%  
Dividend yield (eoy) %0.61.2 49.5%  
Book value per share (Unadj.) Rs65.3222.8 29.3%  
Shares outstanding (eoy) m127.28265.47 47.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.95.7 85.1%   
Avg P/E ratio x37.125.3 146.4%  
P/CF ratio (eoy) x29.621.8 135.7%  
Price / Book Value ratio x3.93.8 103.3%  
Dividend payout %22.030.3 72.5%   
Avg Mkt Cap Rs m32,272222,318 14.5%   
No. of employees `0001.110.8 10.1%   
Total wages/salary Rs m6614,561 14.5%   
Avg. sales/employee Rs Th6,132.23,616.0 169.6%   
Avg. wages/employee Rs Th611.1423.8 144.2%   
Avg. net profit/employee Rs Th803.5814.9 98.6%   
INCOME DATA
Net Sales Rs m6,63538,915 17.1%  
Other income Rs m2421,134 21.4%   
Total revenues Rs m6,87740,049 17.2%   
Gross profit Rs m1,60412,617 12.7%  
Depreciation Rs m2211,425 15.5%   
Interest Rs m3813 283.5%   
Profit before tax Rs m1,58712,313 12.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7183,543 20.3%   
Profit after tax Rs m8698,770 9.9%  
Gross profit margin %24.232.4 74.6%  
Effective tax rate %45.228.8 157.2%   
Net profit margin %13.122.5 58.1%  
BALANCE SHEET DATA
Current assets Rs m6,23245,351 13.7%   
Current liabilities Rs m1,4906,507 22.9%   
Net working cap to sales %71.599.8 71.6%  
Current ratio x4.27.0 60.0%  
Inventory Days Days86127 68.2%  
Debtors Days Days8395 86.8%  
Net fixed assets Rs m4,04321,160 19.1%   
Share capital Rs m127531 24.0%   
"Free" reserves Rs m8,18358,625 14.0%   
Net worth Rs m8,31059,156 14.0%   
Long term debt Rs m180-   
Total assets Rs m10,38967,832 15.3%  
Interest coverage x43.1926.8 4.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.6 111.3%   
Return on assets %8.712.9 67.4%  
Return on equity %10.514.8 70.6%  
Return on capital %19.520.8 93.7%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m5,62232,359 17.4%   
Fx outflow Rs m1,7999,042 19.9%   
Net fx Rs m3,82223,317 16.4%   
CASH FLOW
From Operations Rs m3567,759 4.6%  
From Investments Rs m-279-4,783 5.8%  
From Financial Activity Rs m-225-3,142 7.2%  
Net Cashflow Rs m-148-166 89.3%  

Share Holding

Indian Promoters % 63.4 52.0 121.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.8 -  
FIIs % 0.0 19.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.2 212.2%  
Shareholders   37,287 31,796 117.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON   PFIZER  ALKEM LABORATORIES  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 19, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS